Drugs / Hecolin®
Hecolin®
also known as
Recombinant Hepatitis E Vaccine (Escherichia Coli) · Hepatitis E vaccine · HEV239 · HEV vaccine · p239
Trials 8 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06564116 Comparator | Mar 2023 → Mar 2024 | hepatitis E virus infection | Xiamen Innovax Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT02759991 Comparator | Oct 2017 → Sep 2019 | hepatitis E virus infection | Norwegian Institute of Public Health | Completed | No outcome recorded |
| Phase 4 | NCT03168412 Comparator | May 2017 → Jul 2018 | hepatitis E virus infection | Xiamen Innovax Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hecolin | “The first recombinant hepatitis E vaccine (Escherichia Coli), Hecolin® (Xiamen Innovax, China), was approved for people aged ≥16 years.” PMID 40690851 ↗ Jul 20255“An Randomized, Double-blinded Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® to Evaluate Lot-to-lot Consistency” NCT03365921 ↗ |
| Known as | Hepatitis E vaccine | “The concomitant group (n =300) received Hepatitis B vaccine concomitantly with Hepatitis E vaccine at day 1 and months 1 and 6;” NCT02584543 ↗ |
| Known as | HEV vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02584543 ↗ |
| Known as | HEV239 | “Our aim was to assess efficacy and safety of a recombinant hepatitis E vaccine, HEV 239 (Hecolin; Xiamen Innovax Biotech, Xiamen, China) in a randomised, double-blind,...” PMID 20728932 ↗ Aug 20101“HEV239 (Hecolin®), a recombinant vaccine containing the immunodominant protruding (E2) domain of the HEV capsid protein” PMID 40733519 ↗ Jun 2025 |
| Known as | p239 | “This is consistent with the fact that p239 was demonstrated to be an effective prophylactic vaccine (recently licensed as Hecolin(®) in China) against HEV-induced hepatitis in...” PMID 24662711 ↗ Mar 2014 |
| Known as | Recombinant Hepatitis E Vaccine (Escherichia Coli) | “A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)” NCT02584543 ↗5“An Randomized, Double-blinded Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® to Evaluate Lot-to-lot Consistency” NCT03365921 ↗ |
| Modality | Vaccine | “The hepatitis E vaccine, Hecolin®, has been shown to be safe and highly efficacious among healthy adults aged 16-65 years old.” PMID 31262585 ↗ Jun 2019 |
| Route | Intramuscular | “Participants would intramuscularly receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) at 0, 1, 6 month.” NCT02417597 ↗ |